Benitec Biopharma Ltd ADR (BNTC NASDAQ) stock market data APIs
$14.9456
-0.45(-3%)
as of May 2, 2025
Benitec Biopharma Ltd ADR Financial Data Overview
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.
Prev. Close
14.9456
Open
14.4951
High
15.5932
Low
14.4951
52 wk Range
5.742-16.9
Market Cap
368 M
Shares Outstanding
25 546 K
Revenue
7 000
EPS
-0.3333
Beta
0.765
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Benitec Biopharma Ltd ADR data using free add-ons & libraries
Get Benitec Biopharma Ltd ADR Fundamental Data
Benitec Biopharma Ltd ADR Fundamental data includes:
- Net Revenue: 7 000
- EBITDA: -24 000 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-11
- EPS/Forecast: -0.7757
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Benitec Biopharma Ltd ADR News
New
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Ascendis Pharma A/S (ASND) been one of those stocks this year? Let's take a clos...
Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
-Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 1- -Durable, Clinically Significant Improvements in Swallowing Function ...
Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update
-Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular D...
11 Best ASX Stocks To Buy Now
In this piece, we will take a look at the 11 best ASX stocks to buy now. If you want to skip our introduction to the Australian stock market, then you can take a look at the 5 Best ASX Stocks To Buy N...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
